{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-320901","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.922596+00:00","generated_at":"2026-05-16T13:03:42.039660+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"DBV Technologies reports positive Phase 3 VITESSE results; BLA submission on track for H1 2026","bullets":["VITESSE met primary endpoint: response rate 46.6% vs 14.8% placebo (p<0.001); lower bound CI 24.5% >15% threshold.","Safety consistent with prior studies: low discontinuations (3.2% active vs 0.5% placebo), no treatment-related SAEs.","BLA submission for 4-7 year olds planned for first half 2026; prior FDA Breakthrough Therapy Designation.","Positive results trigger acceleration of ABSA and BS warrants exercise period through Jan 15, 2026.","654 children enrolled, largest food allergy immunotherapy trial; compliance 96.2%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-320901","json":"https://secwatch.observer/filing/0001193125-25-320901.json","markdown":"https://secwatch.observer/filing/0001193125-25-320901.md","text":"https://secwatch.observer/filing/0001193125-25-320901.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312525320901/0001193125-25-320901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312525320901/d28682d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:03:42.039660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}